By Drug Class / Mechanism

Targeted Panel Sequencing (NGS) Market Analysis

Cross-industry research covering Targeted Panel Sequencing (NGS) across 1 market reportspanning Pharmaceuticals & Life Sciences – Molecular Diagnostics / Consumer Genomics.

1 Reports

1 Industries

Reports Covering Targeted Panel Sequencing (NGS)

Direct to Consumer Genetic Sequencing Market to Reach USD 4.7 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Life Sciences – Molecular Diagnostics / Consumer Genomics·Market: USD 2.7 Billion (2025)·CAGR: 7.2%

Disease-specific NGS panels — covering oncology predisposition, pharmacogenomics, and carrier screening — offer superior clinical sensitivity relative to arrays and command net revenue per test of USD 150–500. These panels are the primary growth driver in the clinical-grade DTC tier.

28%

Market Share

8.2%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments